A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72 - AMSL Diabetes


A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72

People who used Control IQ technology improved their TIR and also had significant reductions in mean glucose, hyperglycaemia metrics, hypoglycaemic metrics, and HbA1c. At baseline, the amount of hypoglycaemia was low, but a reduction in time <3.9mmol/L and time <3.1mmol/L were observed with Control-IQ.

liebertpub.com/doi/10.1089/dia.2022.0558

Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Something went wrong. Please try again later!

Back to top